Company Encyclopedia
View More
name
ADC Therapeutics SA
ADCT.US
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs).
1.946 T
ADCT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking226/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE81.41%A
    • Profit Margin-221.97%E
    • Gross Margin-70.48%E
  • Growth ScoreC
    • Revenue YoY6.35%C
    • Net Profit YoY21.31%B
    • Total Assets YoY-16.99%E
    • Net Assets YoY-38.52%E
  • Cash ScoreC
    • Cash Flow Margin-45.05%D
    • OCF YoY6.35%C
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreE
    • Gearing Ratio182.20%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pre-market hot trades in US stocks: Aureus Greenway pre-market down 8.16%; ADC Therapeutics SA pre-market down 7.59%

    Aureus Greenway pre-market down 8.16%; ADC Therapeutics SA pre-market down 7.59%; Polyrizon pre-market up 126.49%; Kala Pharmaceuticals pre-market up 65.41%; Picard Medical pre-market up 23.26%

    Tracking Unusual Activity·
    US
    AGH
    +2.04%
    US
    ADCT
    -10.38%
    Tracking Unusual Activity·
    US
    AGH
    +2.04%
    US
    ADCT
    -10.38%

    ADC Therapeutics shares are trading lower after the company reported updated data from its LOTIS-7 trial evaluating Zynlonta in combination with Glofitamab in relapsed/refractory DLBCL patients.

    benzinga_article·
    US
    ADCT
    -10.38%
    benzinga_article·
    US
    ADCT
    -10.38%

    Adc Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial Of Zynlonta

    Dec 3 (Reuters) - ADC Therapeutics SA:* ADC THERAPEUTICS ANNOUNCES UPDATED DATA FROM LOTIS-7 PHASE 1B CLINICAL TRIAL OF ZYNLONTA® IN COMBINATION WITH BISPECIFIC ANTIBODY SUPPORTING POTENTIAL BEST-IN-CLASS REGIMEN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA* ADC THERAPEUTICS SA - LOTIS-7 TRIAL ON TRACK FOR COMPLETE ENROLLMENT IN 1H 2026 Source text: Further company coverage:

    Reuters·
    US
    ADCT
    -10.38%
    Reuters·
    US
    ADCT
    -10.38%

    ADC Therapeutics Announces LOTIS-7 Trial Update on ZYNLONTA Combination in Relapsed DLBCL

    ADC Therapeutics SA will update on the LOTIS-7 Phase 1b trial of ZYNLONTA® with glofitamab in relapsed DLBCL patients. A webcast on December 3, 2025, will present the study's safety and efficacy data. The original content was published via PR Newswire.

    Reuters·
    US
    ADCT
    -10.38%
    Reuters·
    US
    ADCT
    -10.38%

    FDA awards record number of review designations to ADCs in 2024

    In 2024, the FDA awarded a record 63 review designations to antibody drug conjugates (ADCs), nearly doubling the previous high of 35 in 2023. This increase highlights the FDA's commitment to advancing ADC technology for cancer treatment, reflecting a regulatory shift to support these precision therapies. Enhertu received the most designations, indicating its significant impact in the ADC space.

    Pharmaceutical Technology·
    US
    ADCT
    -10.38%
    Pharmaceutical Technology·
    US
    ADCT
    -10.38%
    © 2025 Longbridge｜Disclaimer